← Leaderboards
Jonathan Kil
Sound Pharmaceuticals, Inc.
$4,174,965
Attributed
$4,174,965
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2021–22$5M$3.8M$2.5M$1.3M$0
'21
'22
Funding mix
By agency
NIH$4,174,965 · 1
By mechanism
U01$4,174,965 · 1
Top collaborators
No co-investigators on record.
Research focus
Double-Blind MethodEnzymesCovid-19 PathogenesisDoseEbselenEffective Therapy2019-NcovCovid-19Covid-19 TreatmentCytokine Release SyndromeDrug TargetingAcute Lung InjuryBaseAdultAffectBleeding Time ProcedureAnimal ModelCell InjuryCellsCovid-19 PatientAnti-Inflammatory AgentsCrystallizationAntineoplastic AntibioticsEtiology
Grant awards (2)
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients$1,092,161
U01 · FY2022 · TR · contact PI
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients$3,082,804
U01 · FY2021 · TR · contact PI